ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 228 filers reported holding ACADIA PHARMACEUTICALS INC in Q2 2016. The put-call ratio across all filers is 0.98 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $8,029,000 | -79.2% | 311,217 | -56.8% | 1.66% | -73.5% |
| Q4 2020 | $38,518,000 | -51.4% | 720,502 | -62.5% | 6.26% | -12.3% |
| Q3 2020 | $79,264,000 | -9.4% | 1,921,563 | +6.5% | 7.13% | +2.0% |
| Q2 2020 | $87,488,000 | +3.8% | 1,804,993 | -9.6% | 6.99% | -20.6% |
| Q1 2020 | $84,320,000 | +57.7% | 1,995,747 | +59.7% | 8.81% | +89.2% |
| Q4 2019 | $53,475,000 | -32.2% | 1,250,000 | -42.9% | 4.66% | -35.7% |
| Q3 2019 | $78,845,000 | -99.8% | 2,190,742 | +46.0% | 7.24% | +62.7% |
| Q2 2019 | $40,095,000,000 | +74564.8% | 1,500,000 | -25.0% | 4.45% | -16.3% |
| Q1 2019 | $53,700,000 | +20.7% | 2,000,000 | -27.3% | 5.32% | -5.5% |
| Q4 2018 | $44,504,000 | +79.2% | 2,752,256 | +130.1% | 5.62% | +45.3% |
| Q3 2018 | $24,831,000 | -18.7% | 1,196,098 | -40.2% | 3.87% | -8.6% |
| Q2 2018 | $30,540,000 | +292.2% | 2,000,000 | +640.7% | 4.23% | +164.5% |
| Q4 2016 | $7,787,000 | +178.5% | 270,000 | +170.0% | 1.60% | +59.5% |
| Q1 2016 | $2,796,000 | – | 100,000 | – | 1.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| March Altus Capital Management LP | 82,723 | $2,685,000 | 20.75% |
| HWG Holdings LP | 289,380 | $9,393,000 | 8.72% |
| Baker Brothers Advisors | 24,516,738 | $795,813,000 | 8.34% |
| HARVEY CAPITAL MANAGEMENT INC | 352,200 | $11,432,000 | 5.73% |
| Belmont Global Advisors, Inc. | 150,000 | $4,869,000 | 4.67% |
| Palo Alto Investors LP | 1,437,730 | $46,669,000 | 3.52% |
| Avoro Capital Advisors LLC | 329,500 | $10,696,000 | 2.38% |
| GARRISON BRADFORD & ASSOCIATES INC | 70,100 | $2,275,000 | 2.23% |
| WEATHERBIE CAPITAL, LLC | 401,642 | $13,037,000 | 1.85% |
| ACUTA CAPITAL PARTNERS, LLC | 85,999 | $2,792,000 | 1.34% |